The settlement of high risk litigation with Pfizer has come a week after you decided to hand over majority control of your company to Japanese firm Daiichi-Sankyo. Was this a pre-requisite to your negotiations with Daiichi?
Today's announcement of settling all major patent disputes with Pfizer has nothing to do with our decision to sell stakes to Daiichi. Both discussions were running parallel.
Since when have you been in discussions with Pfizer?
We have held discussions on and off in the past, but they picked up momentum in the last couple of months. Ranbaxy is now risk-free. What we have done now is in the best interest of the company.
Why did you fail to reach a settlement in five European countries?
Those are not major markets. What we have achieved is the biggest ever settlement in the history of pharmaceutical industry. Let us not focus on minor issues.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app